Drs Ursula A. Matulonis and Panagiotis A. Konstantinopoulos discuss hormonal therapy updates and different ways to target and treat ER+ metastatic endometrial cancer.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001976. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Is the Positivity of Estrogen Receptor or Progesterone Receptor Different Between Type 1 and Type 2 Endometrial Cancer? https://pubmed.ncbi.nlm.nih.gov/27888807/

Immunophenotypic Diversity of Endometrial Adenocarcinomas: Implications for Differential Diagnosis https://pubmed.ncbi.nlm.nih.gov/16648864/

Progesterone: The Ultimate Endometrial Tumor Suppressor https://pubmed.ncbi.nlm.nih.gov/21353793/

Phase 2 Study of Anastrozole in Recurrent Estrogen (ER)/Progesterone (PR) Positive Endometrial Cancer: The PARAGON Trial - ANZGOG 0903 https://pubmed.ncbi.nlm.nih.gov/31130288/

Phase II Study of Fulvestrant in Recurrent/Metastatic Endometrial Carcinoma: A Gynecologic Oncology Group Study https://pubmed.ncbi.nlm.nih.gov/21075433/

Results From a Phase II Study to Assess the Efficacy and Tolerability of Fulvestrant 250 mg/Month as Treatment of Recurrent or Metastatic Endometrial Carcinoma https://ascopubs.org/doi/10.1200/jco.2009.27.15_suppl.5532

Phase II Trial of Alternating Courses of Megestrol Acetate and Tamoxifen in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study https://pubmed.ncbi.nlm.nih.gov/14751131/

Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/25624430/

A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy in Women With Advanced, Persistent or Recurrent Endometrial Carcinoma: A GOG Foundation Study https://pubmed.ncbi.nlm.nih.gov/35063278/

Everolimus, Letrozole, and Metformin in Women With Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study https://pubmed.ncbi.nlm.nih.gov/31628143/

A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36174113/

Elacestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial https://pubmed.ncbi.nlm.nih.gov/35584336/

CDKN2A Cyclin Dependent Kinase Inhibitor 2A [Homo sapiens (human)] https://www.ncbi.nlm.nih.gov/gene/1029

A Phase II Study of Fulvestrant Plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/39561275/

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, in Recurrent/Advanced ER-Positive Endometrioid Endometrial Cancer: Results From the Phase 1a/1b EMBER Study https://pubmed.ncbi.nlm.nih.gov/39442371

Palbociclib Plus Letrozole in Estrogen Receptor-Positive Advanced/Recurrent Endometrial Cancer: Double-Blind Placebo-Controlled Randomized Phase II ENGOT-EN3/PALEO Trial https://pubmed.ncbi.nlm.nih.gov/39657575/